Human succinic semialdehyde dehydrogenase (SSADH) deficiency [gamma-hydroxybutyric (GHB) aciduria] is one of the few neurogenetic disorders affecting the GABA neurotransmitter system, and one in which two neuroactive compounds, GABA and GHB, accumulate. SSADH-/- mice manifest early absence seizures that evolve into lethal generalized convulsive epilepsy, comparable to pediatric patients with absence epilepsy whose seizures follow a similar clinical evolution. Our long-term objective is to delineate basic mechanisms at play in the protean pathology manifested in SSADH deficiency, and to develop novel preclinical treatment paradigms, through evaluation of the following hypotheses (H) and aims (A): HI. Disruption of the neuronal-glial glutamate/GABA/glutamine axis, oxidant stress and the accumulation of toxic carbonyls underlie the transition of absence seizures into generalized convulsions in the SSADH-/- mouse. A1. To characterize glutamate/GABA/glutamine neurotransmitter cycling between neurons and astroglia, oxidant stress, and carbonyl accumulation in the pathology of the SSADH / mouse. H2. Perturbed GABA-mediated neurotransmission causes generalized absence seizures to evolve into generalized convulsive seizures. A2. To define the developmental critical window for the transition of absence seizures to generalized convulsive seizures in SSADH/ mice, assess GABAAR- and GABABR-mediated function during this critical transition period, and determine whether over-expression of GABABR1 will rescue these animals from the onset of generalized convulsive seizures. 1-13. Systemic gamma-hydroxybutyrate clearance is primarily limited by the total amount of SSADH activity present in liver. A3. To perform liver repopulation with SSADW-/- hepatocytes in SSADH+/+ mice utilizing a selective growth advantage. Elucidation of biochemical and neurochemical pathology, and evaluation of long-term enzyme replacement in the mouse model, work in unison toward our long-term objective. The methods to achieve our objectives include biochemical measurements, magnetic resonance spectroscopy, neurophysiology, receptor binding, hepatocyte repopulation, and mouse breeding among others. Our studies in murine SSADH deficiency possess broad clinical relevance: 1) biochemical and neurochemical characterization of pathology is directly pertinent to human SSADH deficiency; 2) determining the mechanism of seizure evolution will provide novel insight into the transition from absence to generalized convulsive seizures in children with absence epilepsy; and 3) understanding alterations of the GABA/glutamate/glutamine axis will provide pathomechanistic insight into other epileptic and neuropsychiatric disorders in which this axis is likely disturbed. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
2R01NS040270-05A2
Application #
7028424
Study Section
Clinical Neuroplasticity and Neurotransmitters Study Section (CNNT)
Program Officer
Tagle, Danilo A
Project Start
2000-09-30
Project End
2009-12-31
Budget Start
2006-01-15
Budget End
2006-12-31
Support Year
5
Fiscal Year
2006
Total Cost
$282,938
Indirect Cost
Name
Children's Hosp Pittsburgh/Upmc Health Sys
Department
Type
DUNS #
044304145
City
Pittsburgh
State
PA
Country
United States
Zip Code
15224
Malaspina, P; Roullet, J-B; Pearl, P L et al. (2016) Succinic semialdehyde dehydrogenase deficiency (SSADHD): Pathophysiological complexity and multifactorial trait associations in a rare monogenic disorder of GABA metabolism. Neurochem Int 99:72-84
Goodwin, Amy K; Gibson, K Michael; Weerts, Elise M (2013) Physical dependence on gamma-hydroxybutrate (GHB) prodrug 1,4-butanediol (1,4-BD): time course and severity of withdrawal in baboons. Drug Alcohol Depend 132:427-33
Siggberg, Linda; Mustonen, Aki; Schuit, Robert et al. (2011) Familial 6p22.2 duplication associates with mild developmental delay and increased SSADH activity. Am J Med Genet B Neuropsychiatr Genet 156B:448-53
Pearl, Phillip L; Shukla, Lovy; Theodore, William H et al. (2011) Epilepsy in succinic semialdehyde dehydrogenase deficiency, a disorder of GABA metabolism. Brain Dev 33:796-805
Kim, Kyung-Jin; Pearl, Phillip L; Jensen, Kimmo et al. (2011) Succinic semialdehyde dehydrogenase: biochemical-molecular-clinical disease mechanisms, redox regulation, and functional significance. Antioxid Redox Signal 15:691-718
Wamelink, M M C; Roos, B; Jansen, E E W et al. (2011) 4-Hydroxybutyric aciduria associated with catheter usage: a diagnostic pitfall in the identification of SSADH deficiency. Mol Genet Metab 102:216-7
Errington, Adam C; Gibson, K Michael; Crunelli, Vincenzo et al. (2011) Aberrant GABA(A) receptor-mediated inhibition in cortico-thalamic networks of succinic semialdehyde dehydrogenase deficient mice. PLoS One 6:e19021
Acosta, Maria T; Munasinghe, Jeeva; Pearl, Phillip L et al. (2010) Cerebellar atrophy in human and murine succinic semialdehyde dehydrogenase deficiency. J Child Neurol 25:1457-61
Knerr, Ina; Gibson, K Michael; Murdoch, Geoffrey et al. (2010) Neuropathology in succinic semialdehyde dehydrogenase deficiency. Pediatr Neurol 42:255-8
Vardya, Irina; Drasbek, Kim R; Gibson, K Michael et al. (2010) Plasticity of postsynaptic, but not presynaptic, GABAB receptors in SSADH deficient mice. Exp Neurol 225:114-22

Showing the most recent 10 out of 64 publications